Does Adding Ipilimumab to Nivolumab Improve Cancer Outcomes?

Nivolumab alone may offer equivalent clinical outcomes and lower toxicity than nivolumab plus ipilimumab in many advanced cancers other than melanoma, a new meta-analysis suggests.
Medscape Medical News

source https://www.medscape.com/viewarticle/996546?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost